Overview

Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Status:
Completed
Trial end date:
2018-07-27
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).
Phase:
Phase 2
Details
Lead Sponsor:
Novaliq GmbH